Trading of LENZ Therapeutics was halted at 09:33 AM EST due to "LULD Pause".

LENZ Therapeutics (LENZ) Competitors

$7.81 -2.18 (-21.86%)

As of 03:06 PM Eastern

LENZ vs. COLL, EVO, SEPN, DBVT, and XERS

Should you buy LENZ Therapeutics stock or one of its competitors? MarketBeat compares LENZ Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENZ Therapeutics include Collegium Pharmaceutical (COLL), Evotec (EVO), Septerna (SEPN), DBV Technologies (DBVT), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does LENZ Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Collegium Pharmaceutical has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.50	$62.87M	$2.04	17.71
LENZ Therapeutics	$19.09M	12.82	-$82.13M	-$2.81	N/A

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than LENZ Therapeutics. MarketBeat recorded 14 mentions for Collegium Pharmaceutical and 10 mentions for LENZ Therapeutics. Collegium Pharmaceutical's average media sentiment score of 0.56 beat LENZ Therapeutics' score of 0.47 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
LENZ Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical presently has a consensus price target of $57.50, indicating a potential upside of 59.13%. LENZ Therapeutics has a consensus price target of $31.00, indicating a potential upside of 297.13%. Given LENZ Therapeutics' higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Collegium Pharmaceutical has a net margin of 9.41% compared to LENZ Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
LENZ Therapeutics	N/A	-37.47%	-35.13%

54.3% of LENZ Therapeutics shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Collegium Pharmaceutical has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats LENZ Therapeutics on 11 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Evotec?

Evotec (NASDAQ:EVO) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

LENZ Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
LENZ Therapeutics	N/A	-37.47%	-35.13%

Evotec currently has a consensus target price of $7.00, suggesting a potential upside of 134.90%. LENZ Therapeutics has a consensus target price of $31.00, suggesting a potential upside of 297.13%. Given LENZ Therapeutics' higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

LENZ Therapeutics has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.19	-$117.12M	N/A	N/A
LENZ Therapeutics	$19.09M	12.82	-$82.13M	-$2.81	N/A

In the previous week, Evotec had 13 more articles in the media than LENZ Therapeutics. MarketBeat recorded 23 mentions for Evotec and 10 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.47 beat Evotec's score of 0.15 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
LENZ Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

5.8% of Evotec shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Evotec has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

LENZ Therapeutics beats Evotec on 8 of the 13 factors compared between the two stocks.

How does LENZ Therapeutics compare to Septerna?

LENZ Therapeutics (NASDAQ:LENZ) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

LENZ Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -106.37%. Septerna's return on equity of -15.85% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-37.47%	-35.13%
Septerna	-106.37%	-15.85%	-11.96%

In the previous week, LENZ Therapeutics had 6 more articles in the media than Septerna. MarketBeat recorded 10 mentions for LENZ Therapeutics and 4 mentions for Septerna. Septerna's average media sentiment score of 0.64 beat LENZ Therapeutics' score of 0.47 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Septerna	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LENZ Therapeutics presently has a consensus target price of $31.00, suggesting a potential upside of 297.13%. Septerna has a consensus target price of $43.13, suggesting a potential upside of 77.16%. Given LENZ Therapeutics' higher probable upside, equities research analysts plainly believe LENZ Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Septerna has higher revenue and earnings than LENZ Therapeutics. Septerna is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	12.82	-$82.13M	-$2.81	N/A
Septerna	$45.95M	23.81	-$48.88M	-$1.11	N/A

54.3% of LENZ Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LENZ Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Septerna has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

Summary

Septerna beats LENZ Therapeutics on 11 of the 17 factors compared between the two stocks.

How does LENZ Therapeutics compare to DBV Technologies?

LENZ Therapeutics (NASDAQ:LENZ) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

In the previous week, LENZ Therapeutics had 9 more articles in the media than DBV Technologies. MarketBeat recorded 10 mentions for LENZ Therapeutics and 1 mentions for DBV Technologies. LENZ Therapeutics' average media sentiment score of 0.47 beat DBV Technologies' score of 0.08 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
LENZ Therapeutics	Neutral
DBV Technologies	Neutral

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 1.4% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LENZ Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. LENZ Therapeutics' return on equity of -37.47% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-37.47%	-35.13%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

LENZ Therapeutics currently has a consensus target price of $31.00, indicating a potential upside of 297.13%. DBV Technologies has a consensus target price of $40.25, indicating a potential upside of 101.80%. Given LENZ Therapeutics' higher probable upside, research analysts plainly believe LENZ Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

LENZ Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, suggesting that its share price is 196% less volatile than the broader market.

LENZ Therapeutics has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	12.82	-$82.13M	-$2.81	N/A
DBV Technologies	$5.64M	196.87	-$146.95M	-$4.46	N/A

Summary

LENZ Therapeutics beats DBV Technologies on 13 of the 17 factors compared between the two stocks.

How does LENZ Therapeutics compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Xeris Biopharma has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.68	$550K	$0.06	103.75
LENZ Therapeutics	$19.09M	12.82	-$82.13M	-$2.81	N/A

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xeris Biopharma has a net margin of 3.81% compared to LENZ Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
LENZ Therapeutics	N/A	-37.47%	-35.13%

Xeris Biopharma presently has a consensus target price of $10.80, indicating a potential upside of 73.49%. LENZ Therapeutics has a consensus target price of $31.00, indicating a potential upside of 297.13%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Xeris Biopharma had 7 more articles in the media than LENZ Therapeutics. MarketBeat recorded 17 mentions for Xeris Biopharma and 10 mentions for LENZ Therapeutics. Xeris Biopharma's average media sentiment score of 0.51 beat LENZ Therapeutics' score of 0.47 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xeris Biopharma beats LENZ Therapeutics on 11 of the 16 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LENZ vs. The Competition

Export

Metric	LENZ Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$244.25M	$3.41B	$6.27B	$12.13B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-2.77	15.30	20.53	25.45
Price / Sales	12.82	302.57	545.62	75.37
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	0.86	6.81	9.60	6.64
Net Income	-$82.13M	$24.11M	$3.55B	$333.40M
7 Day Performance	-13.94%	-1.67%	-0.34%	-0.45%
1 Month Performance	-13.94%	3.64%	6.09%	7.83%
1 Year Performance	-73.42%	70.97%	38.53%	35.63%

LENZ Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LENZ LENZ Therapeutics	2.8374 of 5 stars	$7.81 -21.9%	$31.00 +297.1%	-62.1%	$244.25M	$19.09M	N/A	110	News Coverage Earnings Report Analyst Forecast Gap Down Trading Halted
COLL Collegium Pharmaceutical	2.8345 of 5 stars	$34.87 +0.8%	$53.40 +53.1%	+24.0%	$1.13B	$780.57M	20.33	210	Earnings Report Analyst Upgrade
EVO Evotec	3.1434 of 5 stars	$3.14 +0.7%	$7.00 +122.7%	-29.3%	$1.12B	$788.37M	N/A	4,553	Analyst Downgrade Short Interest Decrease Analyst Revision
SEPN Septerna	3.4487 of 5 stars	$24.19 -2.5%	$43.13 +78.3%	+252.3%	$1.09B	$45.95M	N/A	N/A	News Coverage Earnings Report Gap Up
DBVT DBV Technologies	2.6629 of 5 stars	$19.49 +0.1%	$40.25 +106.5%	+107.1%	$1.08B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LENZ) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENZ Therapeutics (LENZ) Competitors

LENZ vs. COLL, EVO, SEPN, DBVT, and XERS

How does LENZ Therapeutics compare to Collegium Pharmaceutical?

Summary

How does LENZ Therapeutics compare to Evotec?

Summary

How does LENZ Therapeutics compare to Septerna?

Summary

How does LENZ Therapeutics compare to DBV Technologies?

Summary

How does LENZ Therapeutics compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENZ Therapeutics (LENZ) Competitors

LENZ vs. COLL, EVO, SEPN, DBVT, and XERS

How does LENZ Therapeutics compare to Collegium Pharmaceutical?

Which has higher earnings and valuation, COLL or LENZ?

Does the media favor COLL or LENZ?

Do analysts recommend COLL or LENZ?

Is COLL or LENZ more profitable?

Do insiders and institutionals have more ownership in COLL or LENZ?

Which has more volatility and risk, COLL or LENZ?

Summary

How does LENZ Therapeutics compare to Evotec?

Is EVO or LENZ more profitable?

Do analysts recommend EVO or LENZ?

Which has preferable earnings and valuation, EVO or LENZ?

Does the media refer more to EVO or LENZ?

Do insiders and institutionals hold more shares of EVO or LENZ?

Which has more volatility & risk, EVO or LENZ?

Summary

How does LENZ Therapeutics compare to Septerna?

Is LENZ or SEPN more profitable?

Does the media favor LENZ or SEPN?

Do analysts rate LENZ or SEPN?

Which has stronger valuation & earnings, LENZ or SEPN?

Do insiders & institutionals hold more shares of LENZ or SEPN?

Which has more risk & volatility, LENZ or SEPN?

Summary

How does LENZ Therapeutics compare to DBV Technologies?

Does the media prefer LENZ or DBVT?

Do institutionals and insiders believe in LENZ or DBVT?

Is LENZ or DBVT more profitable?

Do analysts prefer LENZ or DBVT?

Which has more risk and volatility, LENZ or DBVT?

Which has stronger earnings and valuation, LENZ or DBVT?

Summary

How does LENZ Therapeutics compare to Xeris Biopharma?

Which has more risk & volatility, XERS or LENZ?

Which has better valuation & earnings, XERS or LENZ?

Do insiders and institutionals believe in XERS or LENZ?

Is XERS or LENZ more profitable?

Do analysts recommend XERS or LENZ?

Does the media favor XERS or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools